A preclinical study using a fusion protein of IL‐10 and albumin (SA‐IL‐10) demonstrated enhanced lymph node targeting and joint protection comparable to anti‐TNF therapy, with more flexible administration routes, in murine RA models [529]. Here, IL10 is linked to rheumatoid arthritis.